Mirum Pharmaceuticals, Inc. - common stock (MIRM) Covered Calls

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare liver diseases. The company markets maralixibat for Alagille syndrome and progressive familial intrahepatic cholestasis, alongside therapies for bile acid synthesis disorders and cerebrotendinous xanthomatosis. Its clinical pipeline includes candidates for primary biliary cholangitis, primary sclerosing cholangitis, and hepatitis delta virus, aiming to address high unmet needs in orphan disease communities.

You can sell covered calls on Mirum Pharmaceuticals, Inc. - common stock to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MIRM (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Mirum Pharmaceuticals, Inc. (MIRM) is a global rare disease company dedicated to developing and delivering life-changing therapies for patients with debilitating and overlooked conditions. The company’s commercial foundation is built on three key assets: maralixibat (LIVMARLI), cholic acid (CHOLBAM), and chenodiol (CTEXLI). Maralixibat, an orally administered ileal bile acid transporter (IBAT) inhibitor, is approved for cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). CHOLBAM is indicated for bile acid synthesis disorders, while CTEXLI targets cerebrotendinous xanthomatosis (CTX), a rare progressive metabolic disease.

The company’s growth strategy centers on expanding its commercial footprint and advancing a late-stage clinical pipeline. Key investigational programs include volixibat, an IBAT inhibitor being evaluated for adult cholestatic liver diseases such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Additionally, through strategic acquisitions, Mirum has expanded into viral liver disease with brelovitug, a monoclonal antibody for chronic hepatitis delta virus (HDV). By focusing on "best-in-class" potential and maintaining strong connections to rare disease communities, Mirum seeks to provide sustainable treatment options for patients whose conditions have limited or no other approved therapies.

Competitive Landscape

Mirum operates in the specialized rare disease sector, where it competes with other biotechnology and pharmaceutical firms focusing on orphan liver and metabolic conditions. Its most direct peers include Jazz Pharmaceuticals, which shares a focus on high-value orphan and neuroscience indications, and Vertex Pharmaceuticals. Both firms utilize specialized commercial teams to reach niche patient populations globally.

In the broader hepatology and viral portfolios, Mirum tracks against established leaders like Gilead Sciences and Novartis. While these larger peers have broader portfolios, Mirum’s competitive moat is built on its deep vertical expertise in rare cholestasis and its portfolio of first-in-class therapies. The company also competes for capital with innovative precision medicine firms like Revolution Medicines and BioMarin Pharmaceutical, as investors weigh the growth potential of rare disease commercialization against earlier-stage oncology platforms.

Strategic Outlook and Innovation

The strategic outlook for Mirum is defined by its transition into a high-growth, multi-product commercial entity. Management is focused on maximizing the reach of its approved therapies across global markets while preparing for potential label expansions. A significant pillar of innovation is the application of bile acid modulation to treat secondary symptoms like intense pruritus, which profoundly impacts quality of life. The company uses advanced clinical modeling and genetic screening to identify patient subsets most likely to benefit from its targeted mechanisms, ensuring a high probability of success in its ongoing trials.

Future innovation involves exploring novel modalities, such as monoclonal antibodies, to address complex liver pathologies like HDV that are not easily managed by small molecules alone. By leveraging a "purpose-built" rare disease model that combines internal research with disciplined business development, Mirum aims to build a comprehensive franchise in hepatology. The company’s commitment to scientific evidence and patient-centric development is intended to drive long-term value for shareholders while fulfilling its mission to transform the care of those living with rare diseases worldwide.

Want more examples? MIR Covered Calls | MIST Covered Calls